Want obesity drugs covered by insurance? Telehealth companies have a big say

Article excerpt

Telehealth companies have become gatekeepers in the obesity drug market, offering lifestyle support to patients while employers pressure them to curb spending on expensive GLP-1 medications like Ozempic and Wegovy. These digital health platforms, which connect patients with doctors and nutritionists, now influence who gets access to the drugs and at what cost, creating tension between maximizing weight loss success and controlling corporate healthcare budgets. As obesity drugs gain mainstream adoption, telehealth firms occupy an uneasy middle ground: they market themselves as essential partners in comprehensive weight management, yet employers increasingly view them as cost-control mechanisms to limit prescriptions for treatments that can cost thousands monthly.